David Polsky, MD, PhD

David Polsky, MD, PhD, on the association between circulating tumor DNA and survival in melanoma.

David Polsky, MD, PhD, discusses the use of circulating tumor DNA (ctDNA) in the COMBI-d trial on melanoma.

David Polsky, MD, PhD, discusses the unmet need of clinical utility in liquid biopsy.

David Polsky, MD, PhD, discusses the exploration of blood-based biomarkers in melanoma.

David Polsky, MD, PhD, discusses potential applications of circulating tumor DNA as a biomarker in melanoma.

David Polsky, MD, PhD, Alfred W. Kopf, MD Professor of Dermatologic Oncology, Ronald O. Perelman Department of Dermatology, professor, Department of Pathology, and director, Pigmented Lesion Service, NYU Langone’s Perlmutter Cancer Center, discusses the next steps that have to be taken to validate the clinical utility of circulating tumor DNA (ctDNA) as a biomarker in BRAF-mutant melanoma.

David Polsky, MD, PhD, Alfred W. Kopf, MD Professor of Dermatologic Oncology, Ronald O. Perelman Department of Dermatology, professor, Department of Pathology, and director, Pigmented Lesion Service, NYU Langone’s Perlmutter Cancer Center, discusses the predictive value of circulating tumor DNA (ctDNA) in BRAF-mutant melanoma.

David Polsky, MD, PhD, discusses using circulating tumor DNA kinetics as a biomarker to predict survival and monitor disease activity in patients with unresectable or metastatic melanoma.